Aptamers

TNBC affects around 170,000 patients worldwide each year and accounts for 15-20% of breast cancer; compared to other types of breast cancer, TNBC is more aggressive and precocious. Its diagnosis, made difficult by the existence of subtypes with different characteristics, is fundamental to establish prognosis and personalized therapy. Nucleic acid aptamers are highly selective low-molecular-weight molecules, synthesizable at low cost and easily modifiable, capable of binding and detecting tissue markers ("aptahistochemistry”). Our team has iden

Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.